This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in SEC filings.
Does Monopar Therapeutics (MNPR) pay a dividend?
Monopar Therapeutics (MNPR) has never paid a dividend. It returns cash through buybacks instead, at roughly a 7.2% buyback yield over the last twelve months. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Monopar Therapeutics (MNPR) pay a dividend?+
No. Monopar Therapeutics (MNPR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Monopar Therapeutics return cash to shareholders?+
Through share buybacks rather than dividends. Over the last twelve months Monopar Therapeutics reduced its share count at a rate equivalent to a 7.2% buyback yield. A buyback returns value by shrinking the share count, so each remaining share owns more of the business, but unlike a dividend it pays you nothing in cash and can be stopped at any time without an announcement.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Monopar Therapeutics.
SourceDividend analysis computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.
Peers
Pharmaceutical Preparations · Pick stocks to compare with MNPR
Held by ETFs
MNPR is in 10 US ETFs. The largest of them, with MNPR's weight in each:
Spot a number that looks wrong? Check it in MNPR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MNPR
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.